Investigating the Crime Scene—Molecular Signatures in Inflammatory Bowel Disease
Research output: Contribution to journal › Review › Research › peer-review
Standard
Investigating the Crime Scene—Molecular Signatures in Inflammatory Bowel Disease. / Andersen, Vibeke; Bennike, Tue B.; Bang, Corinna; Rioux, John D.; Hébert-Milette, Isabelle; Sato, Toshiro; Hansen, Axel K.; Nielsen, Ole H.
In: International Journal of Molecular Sciences, Vol. 24, No. 13, 11217, 2023.Research output: Contribution to journal › Review › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Investigating the Crime Scene—Molecular Signatures in Inflammatory Bowel Disease
AU - Andersen, Vibeke
AU - Bennike, Tue B.
AU - Bang, Corinna
AU - Rioux, John D.
AU - Hébert-Milette, Isabelle
AU - Sato, Toshiro
AU - Hansen, Axel K.
AU - Nielsen, Ole H.
N1 - Publisher Copyright: © 2023 by the authors.
PY - 2023
Y1 - 2023
N2 - Inflammatory bowel diseases (IBD) are without cure and troublesome to manage because of the considerable diversity between patients and the lack of reliable biomarkers. Several studies have demonstrated that diet, gut microbiota, genetics and other patient factors are essential for disease occurrence and progression. Understanding the link between these factors is crucial for identifying molecular signatures that identify biomarkers to advance the management of IBD. Recent technological breakthroughs and data integration have fuelled the intensity of this research. This research demonstrates that the effect of diet depends on patient factors and gut microbial activity. It also identifies a range of potential biomarkers for IBD management, including mucosa-derived cytokines, gasdermins and neutrophil extracellular traps, all of which need further evaluation before clinical translation. This review provides an update on cutting-edge research in IBD that aims to improve disease management and patient quality of life.
AB - Inflammatory bowel diseases (IBD) are without cure and troublesome to manage because of the considerable diversity between patients and the lack of reliable biomarkers. Several studies have demonstrated that diet, gut microbiota, genetics and other patient factors are essential for disease occurrence and progression. Understanding the link between these factors is crucial for identifying molecular signatures that identify biomarkers to advance the management of IBD. Recent technological breakthroughs and data integration have fuelled the intensity of this research. This research demonstrates that the effect of diet depends on patient factors and gut microbial activity. It also identifies a range of potential biomarkers for IBD management, including mucosa-derived cytokines, gasdermins and neutrophil extracellular traps, all of which need further evaluation before clinical translation. This review provides an update on cutting-edge research in IBD that aims to improve disease management and patient quality of life.
KW - biomarkers
KW - Crohn’s disease
KW - gut microbiota
KW - intestinal barrier
KW - personalised medicine
KW - ulcerative colitis
U2 - 10.3390/ijms241311217
DO - 10.3390/ijms241311217
M3 - Review
C2 - 37446397
AN - SCOPUS:85164846413
VL - 24
JO - International Journal of Molecular Sciences (Online)
JF - International Journal of Molecular Sciences (Online)
SN - 1661-6596
IS - 13
M1 - 11217
ER -
ID: 362696872